LPX Lipoxen

RNS Number:1467Y
Lipoxen PLC
11 June 2007

                    Lipoxen Plc ("Lipoxen" or "the Company")



                       Appointment of Financial Director





London, UK, 11 June, 2007 - Lipoxen plc, a biopharmaceutical company
specialising in the development of high value differentiated biologicals,
vaccines and oncology drugs, today announces that, with immediate effect Colin
Hill has been appointed Finance Director on a part-time basis.



Colin Hill is currently a Non-executive Director of Lipoxen, taking on this role
at the time of the Company's admission to AIM in January 2006.  Prior to this he
was Finance Director (2001-3) and Non-executive Chairman (2003-2006) of
Greenchip Investments plc, Lipoxen's predecessor entity that completed the
reverse takeover of Lipoxen Technologies Limited in January 2006.



A member of the Chartered Institute of Management Accountants since 1968, Colin
Hill spent 15 years in industry specializing in corporate turnaround and
development work. He become a freelance consultant in 1981 since which time -
and in a wide variety of hands-on  roles- he has had broad experience on a wide
variety of Corporate Finance transactions in Private Equity and  public
companies in the UK, USA and Australia in the manufacturing, computer services,
health care and property sectors.



Commenting on the appointment, Scott Maguire, CEO, said:



"The Board is delighted that Mr Hill has accepted this executive appointment as
his knowledge and broad financial experience will be invaluable to Lipoxen.
Colin's appointment will help to support the execution of our growth strategy in
order to become a leading biopharmaceutical company."



Colin Hill holds, or has held the following directorships, or has been partner
in the following partnerships within the five years prior to the date of this
announcement:



Information to be disclosed pursuant to Rule 17 and schedule 2(g) of the AIM
Rules.



Colin Hill holds, or has held the following directorships, or has been partner
in the following partnerships within the five years prior to the date of this
announcement:



Current directorships

Arlington Group Limited

Arlington Group Management Services Limited

Arlington Group plc

C&G Tool + Cutter Co. Limited

Cemtron Management Services Ltd

Cemtron Holdings Limited

Cemtron Limited

Signature Music Limited

Swan Enford Limited

Tool & Cutter holdings Limited



Former directorships

Azure BV (Netherlands)

Arlington Group Asset Management Ltd

Eaton Investments (UK) Limited

Essential4Business plc

Micro Cap Equities PLC

MPC Sentinel Limited

MPC Sentinel Midlands Limited

PI Associates Limited

Sentinel Group Holdings Limited

Sentinel Storage Services Limited

Sentinel Business Services Group Limited

Recall Coventry Limited

Recall GQ Limited



Enquiries:


Lipoxen PLC
M. Scott Maguire, CEO                                      +44 (0)20 7691 3583

Grant Thornton Corporate Finance
Philip J Secrett                                           +44 (0)20 7383 5100

Citigate Dewe Rogerson
Yvonne Alexander                                           +44 (0)20 7638 9571




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAEASKFFDLXEFE

Lipoxen (LSE:LPX)
Historical Stock Chart
From Sep 2024 to Oct 2024

Lipoxen (LSE:LPX)
Historical Stock Chart
From Oct 2023 to Oct 2024